Readers will recall that the Centers for Medicare and Medicaid Services announced Novartis' Entresto as one of the first 10 medicines in the Medicare Drug Price Negotiation Program for 2026.

In its lawsuit, the company argued the U.S. Health Resources and Services Administration wrongfully interpreted a federal law concerning the use of rebates in the program. Novartis sells the ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Novartis is expanding its prospects in cardiometabolic ... to price negotiation by the Centers for Medicare and Medicaid Services. The negotiated price will take effect in 2026.

Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.

Novartis AG is a holding company ... The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel ...

Also Read: Novartis To Beef Up Heart Disease Offering ... expanded this model by granting the Department of Health and Human Services (HHS) similar authority to negotiate prices for Medicare ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

Its clinical safety and cost-effectiveness are currently under review by Canada's Drug Agency and Institut National d'Excellence en Santé et Services Sociaux. Novartis Canada country president ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...